DermTech’s validated platform technology is being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research trials from Phase 1-3.
Companion & Complimentary Dx
Mantle Cell Lymphoma
Using DermTech’s proprietary technology, pharma partners can stratify and select patients based on initial skin gene expression profiles, identify biomarkers of specific diseases and disease subsets, and track and predict drug responses.
Growing List of Indications:
Novel assays, based on state of the art gene expression analyses, are being developed to improve disease detection and diagnosis across therapeutic areas. DermTech’s proprietary technology enables a variety of tests including gene expression, DNA mutation and microbiome analyses. This paradigm shifting platform uses stratum corneum tissue collected non-invasively with our Adhesive Skin Collection Kit.
Get In Touch.